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Stroke preventionwith left atrial appendage (LAA) occlusion is
an important alternative treatment for high-risk atrial fibrilla-
tion(AF)patientswithcontraindications tooralanticoagulation
(OAC).1,2 The presence of LAA thrombus detected on preproce-
dural imaging usually precludes implantation of the endocar-
dial device because of a prohibitively high periprocedural
embolic risk.3 Although successful resolution of LAA thrombus
with OAC has been described, all previous reports are in
patients without contraindications to OAC.4–6 Furthermore,
long-term data in these patients are lacking. We hypothesized
that short-term OAC with apixaban could safely facilitate
resolution of LAA thrombi even in a high-risk population,
thereby allowing safe LAA occluder device implantation, with
good outcomes over the long term.
This was a retrospective cohort study of 83 patients who
underwent work-up for LAA occlusion at our center between
January 2015 and December 2017. LAA thrombi were docu-
mented in 11 (13.3%) patients (mean age: 76.9 [ 6.9] years;
7 males) on preprocedural imaging (9 on transesophageal
echocardiography and 2 on cardiac computed tomographic
angiography) (►Table 1). All patients with LAA thrombi had
permanent AF, with median CHA2DS2-VASc and HAS-BLED
scores of 4 (interquartile range [IQR]: 3–5) and 2 (IQR: 2–3),
respectively. Contraindications to lifelong OAC in this cohort
were prior intracranial hemorrhage in six patients (two on
warfarin, one on dabigatran, one on heparin, and two while
not on anticoagulation), prior major gastrointestinal hemor-
rhage requiring emergency hospital admission and blood
transfusion in three patients (two onwarfarin and one while
not on anticoagulation), severe unexplained anemia on
dabigatran in one patient, and failed OAC in one patient. At
the time of imaging, none of the patientswere receiving OAC,
and four (36.4%) patients were on a single antiplatelet agent.
There were no significant differences between patients who
had documented LAA thrombus compared with those with-
out in terms of age (p¼ 0.80), sex category (p¼ 0.74), AF type
(p¼ 0.11), comorbidities (hypertension [p¼ 0.50], diabetes
mellitus [p¼ 0.31], and prior stroke or transient ischemic
attack [p¼ 0.47]), and CHA2DS2-VASc score (p¼ 0.69).
The potential risks of surgical thrombectomy and ligation
werefelt tooutweigh thebenefits.Hence, followingdetectionof
LAA thrombi, off-label dose-adjusted apixaban (2.5mg twice
daily for three patients and 5mg twice daily for eight patients)
was prescribed for each patient. The choice of anticoagulation
was based on evidence of potential favorable characteristics of
apixaban compared with other OAC in terms of efficacy and
safety profile.7 Repeat imaging in the form of transesophageal
echocardiography, or cardiac computed tomographic angiog-
raphy was scheduled at 6- to 8-week intervals. Complete
resolutionofLAAthrombuswasobservedin10(90.9%)patients
after apixaban treatment for amedian of 94 days (IQR: 44–126
days). During treatment with apixaban, one patient (who
received a dose of 5mg twice daily) had a severe gastrointesti-
nal bleed requiring blood transfusion, and one patient suffered
an ischemic strokewith subsequent full recovery. Therewas no
significant difference in the risk of bleeding according to
apixaban dosage (p¼ 0.73). One patient (patient 8, ►Table 1)
had persistent LAA thrombus on repeated imaging, and a
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patient-centered decision was ultimately taken for continued
apixaban therapy despite prior major intracranial bleed while
on warfarin. In this patient, no bleeding complications were
observed over a follow-up period of 25 weeks.
The 10 patients with thrombus resolution underwent
successful LAA occlusion with no periprocedural complica-
tions. Apixaban was replaced by dual-antiplatelet therapy
with aspirin and clopidogrel for 6 weeks postprocedure
followed by single (or no) antiplatelet therapy. The decision
to discontinue long-term antiplatelet therapy in three
patients was based on an individualized approach after
accounting for their high bleeding risk. All patients under-
went cardiac imaging with transesophageal echocardiogra-
phy or cardiac computed tomographic angiography at 6 to
8 weeks postprocedure; no device-related thrombus was
observed in any patient. Across a median follow-up of 2.5
years (IQR: 0.6–3.3 years), one patient suffered a transient
ischemic attack and another had an episode of severe epi-
staxis despite not being on antiplatelet or OAC therapy at the
time. During this same period, four (40%) patients died.
Given the low number of patients, our study was under-
powered and should therefore be interpreted with caution.
Furthermore, the incidence of LAA thrombus in our study
maynot reflect those of the general AF population asmanyof
our high-risk patientswere not on anticoagulation therapy at
baseline. It is alsoworth noting that we adopted a strategy of
minimizing the exposure to OAC in this high-risk cohort by
performing LAA occlusion without delay in patients with a
confirmed resolution of LAA thrombi.
Our experience suggests that short-term treatment
with apixaban may be effective and safe for aiding the
resolution of documented LAA thrombus in high-risk
patients who are ineligible for lifelong OAC therapy. This
strategy allows the LAA occlusion procedure to be under-
taken safely, thereby potentially reducing the long-term
risk of thromboembolism.
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